CD8+ HELPER INDEPENDENT T CELLS IN TUMOR THERAPY

Project: Research project

Description

DESCRIPTION: The investigator proposes studies with L-selectin down regulated CD8+ T cells in mice to see whether their effectiveness can be improved with cytokines, examine the histology of tumors to see where administered CD8+ cells traffic, whether they undergo apoptosis or become tolerated at the tumor site. Dose-response studies with various numbers of T cells will also be performed against established tumors. The use of dendritic cells with peptides will also be explored to immunize the mice from which the T cells are obtained. Treatment of the tumor with cyclooxygenase inhibitors will also be studied to see whether tumor-induced suppression can be overcome.
StatusFinished
Effective start/end date1/1/019/30/08

Funding

  • National Institutes of Health: $309,825.00
  • National Institutes of Health: $299,700.00
  • National Institutes of Health: $302,544.00
  • National Institutes of Health: $293,771.00
  • National Institutes of Health: $299,700.00
  • National Institutes of Health: $299,700.00
  • National Institutes of Health: $309,825.00

Fingerprint

Helper-Inducer T-Lymphocytes
Adoptive Immunotherapy
L-Selectin
T-Lymphocytes
Neoplasms
T-Cell Antigen Receptor
Therapeutics
Apoptosis
Radiotherapy
Drug Therapy
Adoptive Transfer
Antigen Presentation
T-Lymphocyte Subsets
Interleukin-2
Melanoma
Lymph Nodes
Cyclooxygenase Inhibitors
Dendritic Cells
Histology
Research Personnel

ASJC

  • Medicine(all)